顺铂腹腔热灌注化疗联合静脉化疗治疗晚期上皮性卵巢癌的疗效分析

姚霁航 ,  牛译墨 ,  张镕津 ,  李华洋 ,  田东立 ,  张颐 ,  宿钟化

中国医科大学学报 ›› 2026, Vol. 55 ›› Issue (8) : 673 -679.

PDF (469KB)
中国医科大学学报 ›› 2026, Vol. 55 ›› Issue (8) : 673 -679. DOI: 10.12007/j.issn.0258‐4646.2026.08.001
论著

顺铂腹腔热灌注化疗联合静脉化疗治疗晚期上皮性卵巢癌的疗效分析

作者信息 +

Efficacy of cisplatin-based hyperthermic intraperitoneal chemotherapy combined with intravenous chemotherapy for advanced epithelial ovarian cancer

Author information +
文章历史 +
PDF (479K)

摘要

目的 探讨顺铂腹腔热灌注化疗 (HIPEC) 联合静脉化疗在晚期上皮性卵巢癌 (EOC) 治疗中的临床价值。方法 收集2021年1月至2025年12月间中国医科大学附属第一医院妇科病房收治的60例晚期EOC患者的临床资料。根据治疗方案分为研究组 (肿瘤细胞减灭术+顺铂HIPEC+紫杉醇联合卡铂化疗,15例) 与对照组 (肿瘤细胞减灭术+紫杉醇联合卡铂化疗,45例),比较2组患者治疗后客观缓解率 (ORR); 治疗前后血清癌抗原12-5 (CA12-5)、人附睾蛋白4 (HE4)、可溶性程序性死亡受体配体1 (sPD-L1)、可溶性T细胞免疫球蛋白黏蛋白结构域3 (sTIM-3) 及T淋巴细胞亚群水平。比较2组患者2年总生存率及治疗相关不良反应发生率。结果 研究组患者ORR显著高于对照组 (93.33% vs. 82.22%,P < 0.05)。治疗后2组血清CA12-5、HE4、sPD-L1、sTIM-3水平均较治疗前显著下降 (P < 0.05),且研究组各项指标下降幅度均显著大于对照组 (P < 0.05)。治疗后2组CD3+T细胞、CD4+T细胞百分比及CD4+T细胞/CD8+T细胞比值均较治疗前升高,CD8+T细胞百分比下降; 研究组上述指标的改善程度均显著优于对照组 (P < 0.05)。在生存期方面,研究组2年总生存率为100%,高于对照组 (86.67%),但2组间比较差异无统计学意义 (P > 0.05)。在安全性方面,2组不良反应发生率差异无统计学意义 (P > 0.05)。结论 顺铂HIPEC联合静脉化疗可显著提高晚期EOC患者的治疗反应率,有效降低肿瘤负荷; 2年总生存率有提高趋势,且未增加严重不良反应风险。其机制可能与下调sPD-L1、sTIM-3等免疫抑制分子、改善T淋巴细胞亚群分布、调节免疫有关。此联合方案安全可行,具有较好的临床应用前景。

Abstract

Objective To evaluate the clinical value of cisplatin-based hyperthermic intraperitoneal chemotherapy (HIPEC) combined with intravenous chemotherapy in the treatment of advanced epithelial ovarian cancer (EOC),focusing on its effects on serum tumor markers,immune checkpoint molecules,and immunomodulation. Methods A total of 60 patients with advanced EOC who were admitted to the Department of Gynecology,the First Hospital of China Medical University,between January 2021 and December 2025 were enrolled and divided into the study (n = 15) and control (n = 45) groups according to treatment regimens. The study group received cytoreductive surgery + cisplatin-based HIPEC + paclitaxel combined with carboplatin chemotherapy,whereas the control group received cytoreductive surgery + paclitaxel combined with carboplatin chemotherapy. The objective response rate (ORR) was compared between the two groups. Serum levels of cancer antigen 12-5 (CA12-5),human epididymis protein 4 (HE4),soluble programmed death-ligand 1 (sPD-L1),soluble T-cell immunoglobulin and mucin-domain containing-3 (sTIM-3),and T lymphocyte subsets (CD3+,CD4+,and CD8+ T cells,as well as the CD4+/CD8+ T cell ratio) were measured before and after treatment. In addition,the 2-year overall survival rate and incidence of treatment-related adverse reactions were compared to evaluate survival benefits and safety. Results The ORR in the study group was significantly higher than that in the control group [93.33% (14/15) vs. 82.22% (37/45),P = 0.019]. After treatment,serum levels of CA12-5,HE4,sPD-L1,and sTIM-3 decreased significantly in both groups compared with those before treatment (P < 0.05),and the decreases in all indicators were significantly greater in the study group than in the control group (P < 0.05). After treatment,the percentages of CD3+ and CD4+ T cells and the CD4+/CD8+ T cell ratio increased in both groups,whereas the percentage of CD8+ T cells decreased; the improvements in these indicators were significantly better in the study group than in the control group (P < 0.05). The 2-year overall survival rate was 100% in the study group compared with 86.67% in the control group; however,this difference was not statistically significant (P > 0.05). In terms of safety,no statistically significant difference was observed in the incidence of adverse reactions between the two groups (P > 0.05). Conclusion Cisplatin-based HIPEC combined with intravenous chemotherapy can significantly improve the treatment response rate in patients with advanced EOC and effectively reduce tumor burden. The combined regimen exhibits a trend toward improved 2-year overall survival without increasing the risk of severe adverse reactions. The mechanism may be related to the downregulation of immunosuppressive molecules such as sPD-L1 and sTIM-3,improvement of T lymphocyte subset distribution,and immunomodulation. This combined regimen is safe and feasible,with promising clinical application prospects.

关键词

腹腔热灌注化疗 / 顺铂 / 晚期上皮性卵巢癌 / 免疫调节

Key words

hyperthermic intraperitoneal chemotherapy / cisplatin / advanced epithelial ovarian cancer / immunomodulation

引用本文

引用格式 ▾
姚霁航,牛译墨,张镕津,李华洋,田东立,张颐,宿钟化. 顺铂腹腔热灌注化疗联合静脉化疗治疗晚期上皮性卵巢癌的疗效分析[J]. 中国医科大学学报, 2026, 55(8): 673-679 DOI:10.12007/j.issn.0258‐4646.2026.08.001

登录浏览全文

4963

注册一个新账户 忘记密码

参考文献

[1]

SIEGEL RL,MILLER KD,WAGLE NS,et al. Cancer statistics,2023 [J]. CA Cancer J Clin,2023,73 (1):17-48. DOI:10.3322/caac.21763.

[2]

GAILLARD S,LACCHETTI C,ARMSTRONG DK,et al. Neoadjuvant chemotherapy for newly diagnosed,advanced ovarian cancer:ASCO guideline update [J]. J Clin Oncol,2025,43 (7):868-891. DOI:10.1200/JCO-24-02589.

[3]

CHIA DKA, DEMUYTERE J,ERNST S,et al. Effects of hyperthermia and hyperthermic intraperitoneal chemoperfusion on the peritoneal and tumor immune contexture [J]. Cancers,2023,15 (17):4314. DOI:10.3390/cancers15174314.

[4]

SAUER N,JANICKA N,SZLASA W,et al. TIM-3 as a promising target for cancer immunotherapy in a wide range of tumors [J]. Cancer Immunol Immunother,2023,72 (11):3405-3425. DOI:10.1007/s00262-023-03516-1.

[5]

OKEN MM,CREECH RH,TORMEY DC,et al. Toxicity and response criteria of the eastern cooperative oncology group [J]. Am J Clin Oncol,1982,5 (6):649-656. DOI:10.1097/00000421-198212000-00014.

[6]

EISENHAUER EA,THERASSE P,BOGAERTS J,et al. New response evaluation criteria in solid tumours:revised RECIST guideline (version 1.1) [J]. Eur J Cancer,2009,45 (2):228-247. DOI:10.1016/j.ejca.2008.10.026.

[7]

NATIONAL CANCER INSTITUTE. Common terminology criteria for adverse events (CTCAE) version 5.0 [EB/OL]. [2017-11-27]. (2026-03-01). https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf.

[8]

AHMED K,TABUCHI Y,KONDO T. Hyperthermia:an effective strategy to induce apoptosis in cancer cells [J]. Apoptosis,2015,20 (11):1411-1419. DOI:10.1007/s10495-015-1168-3.

[9]

MANTSO T,GOUSSETIS G,FRANCO R,et al. Effects of hyperthermia as a mitigation strategy in DNA damage-based cancer therapies [J]. Semin Cancer Biol,2016,37-38:96-105. DOI:10.1016/j.semcancer.2016.03.004.

[10]

VAN DRIEL WJ,KOOLE SN,SIKORSKA K,et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer [J]. N Engl J Med,2018,378 (3):230-240. DOI:10.1056/nejmoa1708618.

[11]

DELLINGER TH,HAN ES,RAOOF M,et al. Hyperthermic intraperitoneal chemotherapy-induced molecular changes in humans validate preclinical data in ovarian cancer [J]. JCO Precis Oncol,2022,6:e2100239. DOI:10.1200/PO.21.00239.

[12]

LAVOUÉ V,BAKRIN N,BOLZE PA,et al. Saved by the evidence:hyperthermic intraperitoneal chemotherapy still has a role to play in ovarian cancer [J]. Eur J Surg Oncol,2019,45 (10):1757-1759. DOI:10.1016/j.ejso.2019.03.037.

[13]

ARONSON SL,LOPEZ-YURDA M,KOOLE SN,et al. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in patients with advanced ovarian cancer (OVHIPEC-1):final survival analysis of a randomised,controlled,phase 3 trial [J]. Lancet Oncol,2023,24 (10):1109-1118. DOI:10.1016/S1470-2045(23)00396-0.

[14]

WU QW,WU QQ,XU JY,et al. Efficacy of hyperthermic intraperitoneal chemotherapy in patients with epithelial ovarian cancer:a meta-analysis [J]. Int J Hyperth,2019,36 (1):561-571. DOI:10.1080/02656736.2019.1612101.

[15]

DOROSHOW DB,BHALLA S,BEASLEY MB,et al. PD-L1 as a biomarker of response to immune-checkpoint inhibitors [J]. Nat Rev Clin Oncol,2021,18 (6):345-362. DOI:10.1038/s41571-021-00473-5.

[16]

LIM MC,CHANG SJ,PARK B,et al. Survival after hyperthermic intraperitoneal chemotherapy and primary or interval cytoreductive surgery in ovarian cancer:a randomized clinical trial [J]. JAMA Surg,2022,157 (5):374. DOI:10.1001/jamasurg.2022.0143.

[17]

HAMANISHI J,MANDAI M,MATSUMURA N,et al. PD-1/PD-L1 blockade in cancer treatment:perspectives and issues [J]. Int J Clin Oncol,2016,21 (3):462-473. DOI:10.1007/s10147-016-0959-z.

[18]

DAS M,ZHU C,KUCHROO VK. TIM-3 and its role in regulating anti-tumor immunity [J]. Immunol Rev,2017,276 (1):97-111. DOI:10.1111/imr.12520.

[19]

IMANI S,FARGHADANI R,ROOZITALAB G,et al. Reprogramming the breast tumor immune microenvironment:cold-to-hot transition for enhanced immunotherapy [J]. J Exp Clin Cancer Res,2025,44 (1):131. DOI:10.1186/s13046-025-03394-8.

[20]

VERGOTE I,HARTER P,CHIVA L. Hyperthermic intraperitoneal chemotherapy does not improve survival in advanced ovarian cancer [J]. Cancer,2019,125 (S24):4594-4597. DOI:10.1002/cncr.32496.

[21]

NEVO N,LEE GOLDSTEIN A,BAR-DAVID S,et al. Immunological effects of heated intraperitoneal chemotherapy can be augmented by thymosin α1 [J]. Int Immunopharmacol,2023,116:109829. DOI:10.1016/j.intimp.2023.109829.

[22]

GEVA R,ALON G,NATHANSON M,et al. PD-1 blockade combined with heated intraperitoneal chemotherapy improves outcome in experimental peritoneal metastases from colonic origin in a murine model [J]. Ann Surg Oncol,2023,30 (5):2657-2663. DOI:10.1245/s10434-022-13025-7.

[23]

DELLA CORTE L,CONTE C,PALUMBO M,et al. Hyperthermic intraperitoneal chemotherapy (HIPEC):new approaches and controversies on the treatment of advanced epithelial ovarian cancer-systematic review and meta-analysis [J]. J Clin Med,2023,12 (22):7012. DOI:10.3390/jcm12227012.

[24]

HARTER P,BOGNER G,CHIVA L,et al. Statement of the AGO Kommission Ovar,AGO Study Group,NOGGO,AGO Austria,Swiss AGO,BGOG,CEEGOG,GEICO,and SFOG regarding the use of hyperthermic intraperitoneal chemotherapy (HIPEC) in epithelial ovarian cancer [J]. Bull Cancer,2024,111 (3):277-284. DOI:10.1055/s-0035-1568169.

基金资助

辽宁省重点研发项目(2024JH2/102500019)

AI Summary AI Mindmap
PDF (469KB)

0

访问

0

被引

详细

导航
相关文章

AI思维导图

/

〈 〉